Evaluation of the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease

Novartis Investigative Site, East Gosford

Novartis Investigative Site, Melbourne

Novartis Investigative Site, Parkville

Novartis Investigative Site, Berlin

Novartis Investigative Site, Beelitz-Heilstätten

Novartis Investigative Site, Lahti

Novartis Investigative Site, Turku

Novartis Investigative Site, Madrid

Novartis Investigative Site, Toulouse

Novartis Investigative Site, Tampere

Novartis Investigative Site, Pessac

Novartis Investigative Site, Kassel

Novartis Investigative Site, Marburg

Novartis Investigative Site, Saint-Herblain

Novartis Investigative Site, Lido di Camaiore

Novartis Investigative Site, Lille

Novartis Investigative Site, Clermont-Ferrand

Novartis Investigative Site, Tübingen

Novartis Investigative Site, Napoli

Novartis Investigative Site, München

Novartis Investigative Site, Oulu

Novartis Investigative Site, Heidelberg

Novartis Investigative Site, Kuopio

Novartis Investigative Site, Bochum

Novartis Investigative Site, Barcelona

Novartis Investigative Site, Donostia / San Sebastian

Novartis Investigational Site, Westmead

Quebec Memory & Motor Skills Disorders Clinic, Québec

Clinique Neuro-Outaouais, Gatineau

Recherches Pembina, Inc, Greenfield Park

Novartis Investigative Site, Montreal

Parkinson's and Neurodegenerative Disorders Clinic, Ottawa

Toronto Western Hospital, UHN, Toronto

Novartis Investigative Site, Vancouver

Novartis Investigative Site, Dresden

Novartis Investigative Site, Stadtroda

Novartis Investigative Site, Roma

Novartis Investigative Site, Roma

Novartis Investigative Site, Fukuoka

Novartis Investigative Site, Tochigi

Novartis Investigative Site, Tokyo

Novartis Investigative Site, Tokyo

Novartis Investigative SIte, Tokyo

Novartis Investigative Site, Tōon

Novartis Investigative Site, Wakayama

Novartis Investigative Site, Barcelona

Novartis Investigative Site, Barcelona